Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Quantifying Optimal Relugolix Duration With Radiation in High Risk Prostate Cancer (QURE-PC)

NCT06129851 is registered in ClinicalTrials.gov with University of Kansas Medical Center as lead sponsor.

NCT NCT06129851
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06129851 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Quantifying Optimal Relugolix Duration With Radiation in High Risk Prostate Cancer (QURE-PC)
Lead sponsor
University of Kansas Medical Center
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 20, 2023
Completion date
October 23, 2026
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stage iic prostate cancer ajcc v8, stage iii prostate cancer ajcc v8, stage iv prostate cancer ajcc v8